Close Menu
Home › About Us › Our Staff › Turna Ray

Turna Ray

Managing Editor, Precision Oncology News
Phone Number
+1-212-651-5626
Email
[email protected]
Turna Ray at Genomeweb / 360dx Turna Ray at Genomeweb / 360dx

Turna Ray has been covering the personalized medicine and molecular diagnostics industries for GenomeWeb since 2006. She closely tracks the evolving regulatory, reimbursement, and business environment for precision medicine products. 

Articles Authored by Turna Ray

Nov 12, 2019

Bristol-Myers, PathAI Show Artificial Intelligence Is on Par With Manual PD-L1 Scoring

Premium

The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.

Nov 05, 2019

CIViC Developers Enhancing Variant Database for Greater Use in Precision Oncology

Premium

With a $3.7 million NIH grant, database developers hope to garner FDA recognition, develop a new user interface, and further integrate its use in cancer care.

Oct 29, 2019

FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers

Premium

For heavily pretreated ovarian cancer patients, doctors will now have to weigh their HRD status in the context of an increasingly complex backdrop of biomarker information.

Oct 24, 2019

Genetic Testing Challenges in Oncology: Appropriate Clinical Management of BRIP1 Variant of Unknown Significance

A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care. 

Oct 22, 2019

Report Says Many Precision Drugs Will Launch in Coming Years But Unclear if They Will Reach Patients

Premium

Diaceutics is projecting that FDA will soon approve more personalized drugs than all-comer drugs, but absent changes in diagnostics strategies many patients won't receive them.

Sep 23, 2019

Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines

Premium

An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.

Sep 17, 2019

Cancer Centers Investing in Research Autopsies to Explore Why Patients Fail Precision Medicine

Premium

Top cancer centers around the country are starting research autopsy programs in an effort to overcome the blindspots and limitations of current precision oncology approaches. 

Aug 13, 2019

Complex Genetic Testing Errors Emerge Amid Increasing Panel Use, Consumer Access, Case Series Finds

The Cancer Journal documented 25 cases where inappropriate tests were ordered, variants were interpreted incorrectly, and wrong results were reported to patients. 

Jul 26, 2019

CancerLinQ Calls on MDx Labs to Share Structured Genomic Reports to Support Precision Oncology

Premium

At a real-world data workshop, Wendy Rubinstein said that labs have a responsibility under the 21st Century Cures Act to facilitate integration of genomic data into EHRs.

Jul 19, 2019

Survey of Precision Oncology Programs Finds Agreement on Testing, Divergence in Care Delivery

Our first survey of cancer centers around the country shows patients are getting a variety of molecular tests, but only a minority are matching to clinical trials based on the results.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.